The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Translational Neural Devices (U44, UG3/UH3 Clinical Trial Required)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and small clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities leading to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.
Companion FOA: RFA-NS-21-021 - Translational Neural Devices (UG3/UH3 Clinical Trial Optional)
- Letter of Intent: 60 days prior to the receipt date
- U01 Deadlines: July 1, 2021;October 20, 2021; February 18, 2022; June 20, 2022; October 18, 2022; February 21, 2023; June 19, 2023; October 18, 2023; February 20, 2024
- UG3/UH3 Deadlines: July 1, 2021;October 20, 2021; February 18, 2022; June 20, 2022; October 18, 2022; February 21, 2023; June 19, 2023; October 18, 2023; February 20, 2024
RFA-NS-21-022 Expiration Date: February 21, 2024
Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.
Applicants should rarely exceed $1,000,000 in total costs per year during the SBIR Phase I and $1,500,000 in total costs per year during the SBIR Phase II.